Bladder Cancer Partnering 2007-2012


#93027

150pages

Current Partnering

$ 995

In Stock

 

This is an on demand report, it will take 20 to 25 working days to complete

 

The Bladder Cancer Partnering 2007-2012 provides understanding and access to the bladder cancer partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an analysis of bladder cancer partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors bladder cancer technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered contract documents provide this insight where press releases do not.

This data driven report contains over 25 links to online copies of actual bladder cancer deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partners flexibility on a wide range of important issues, many of which will have a significant impact on each partys ability to derive value from the deal.

The initial chapters of this report provide an orientation of bladder cancer partnering trends.

Chapter 1 provides an introduction to the report, whilst 

 

Chapter 2 provides an overview of the trends in bladder cancer partnering since 2007, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.

Chapter 3 provides an overview of the leading bladder cancer deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive directory of bladder cancer partnering deals signed and announced since 2007. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the
research, development and commercialization of bladder cancer technologies and products.

Report scope

Bladder Cancer Partnering 2007-2012 is intended to provide the reader with an in-depth understanding and access to bladder cancer trends and structure of deals entered into by leading companies worldwide.

This data driven report includes:

  • Trends in bladder cancer dealmaking in the biopharma industry since 2007
  • Access to summary headline, upfront, milestone and royalty data
  • Access to over 25 bladder cancer contract documents
  • The leading bladder cancer deals by value since 2007

In Bladder Cancer Partnering 2007-2012, the available deals are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Company A-Z
  • Industry sector
  • Stage of development at signing
  • Deal component type
  • Technology type

 

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

TABLE OF CONTENT

 

 

Executive Summary

Chapter 1 Introduction

Chapter 2 Trends in bladder cancer partnering
2.1. Introduction
2.2. Bladder cancer partnering over the years
2.3. Bigpharma bladder cancer dealmaking activity
2.4. Bladder cancer partnering by deal type
2.5. Bladder cancer partnering industry sector
2.6. Bladder cancer partnering by stage of development
2.7. Bladder cancer partnering by technology type
2.8. Disclosed financial deal terms for bladder cancer partnering
2.8.1 Bladder cancer headline values
2.8.2 Bladder cancer upfront payments
2.8.3 Bladder cancer milestone payments
2.8.4 Bladder cancer royalty rates

 

 

Chapter 3 Leading bladder cancer deals
3.1. Introduction
3.2. Top bladder cancer deals by value
3.3. Top bladder cancer deals involving bigpharma
 

Chapter 4 Dealmaking directory
4.1. Introduction
4.2. Company A-Z
4.3. By deal type
Asset purchase
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Manufacturing
Marketing
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Termination
4.4. By industry sector
Academic
Bigpharma
Biotech
Drug delivery
Medical device
Diagnostic
Generic pharma
Government
Non-profit
Pharmaceutical
Research tools
Services
Specialty pharma
4.5. By stage of development
Discovery
Pre-clinical
Phase I
Phase II
Phase III
Registration
Marketed
4.6. By technology type
Analysis
Animal models
Assays
Bioinformatics
Biological compounds
Biomarkers
Biomaterials
Cell culture
Cell therapy
Clinical testing
Diagnostic - companion
Devices
Diagnostics
Discovery tools
DNA probes
Drug delivery
Enabling technology
Epigenetics
Equipment
Facilities
Gene therapy
Genomics
Imaging
Industrial chemicals
In vitro models
Monoclonal antibodies
Nanotechnology
Oligonucleotide
Peptides
Personalised medicine
Processes
Proteomics
Radio/Chemo-therapy
Recombinant DNA
Research services
Research supplies
RNA therapeutics
Screening
Small molecules
Stem cells
Vaccines
 

Chapter 5 Partnering resource center
5.1. Online partnering
5.2. Partnering events
5.3. Further reading on dealmaking
 

Appendices

Appendix 1 Deal type definitions

About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form Reports

NA


Figure 1: Bladder cancer partnering since 2007
Figure 2: Bigpharma top 50 bladder cancer deals 2007 to 2011
Figure 3: Bigpharma bladder cancer deal frequency 2007 to 2011
Figure 4: Bladder cancer partnering by deal type since 2007
Figure 5: Bladder cancer partnering by industry sector since 2007
Figure 6: Bladder cancer partnering by stage of development since 2007
Figure 7: Bladder cancer partnering by technology type since 2007
Figure 8: Bladder cancer deals with a headline value
Figure 9: Bladder cancer deals with upfront payment values
Figure 10: Bladder cancer deals with milestone payments
Figure 11: Bladder cancer deals with royalty rates, %
Figure 12: Top bladder cancer deals by value since 2007
Figure 13: Top bladder cancer deals signed by bigpharma value since 2007
Figure 14: Online partnering resources
Figure 15: Forthcoming partnering events
Figure 16: Deal type definitions